Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention
Cardiovascular disease (CVD), which includes cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction, is a major concern for long-term survivors of childhood cancer. There is clear evidence of increased risk of CVD largel...
Uložené v:
| Vydané v: | Journal of clinical oncology Ročník 36; číslo 21; s. 2135 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
20.07.2018
|
| Predmet: | |
| ISSN: | 1527-7755, 1527-7755 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Cardiovascular disease (CVD), which includes cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction, is a major concern for long-term survivors of childhood cancer. There is clear evidence of increased risk of CVD largely attributable to treatment exposures at a young age, most notably anthracycline chemotherapy and chest-directed radiation therapy, and compounded by traditional cardiovascular risk factors accrued during decades after treatment exposure. Preclinical studies are limited; thus, it is a high priority to understand the pathophysiology of CVD as a result of anticancer treatments, taking into consideration the growing and developing heart. Recently developed personalized risk prediction models can provide decision support before initiation of anticancer therapy or facilitate implementation of screening strategies in at-risk survivors of cancer. Although consensus-based screening guidelines exist for the application of blood and imaging biomarkers of CVD, the most appropriate timing and frequency of these measures in survivors of childhood cancer are not yet fully elucidated. Longitudinal studies are needed to characterize the prognostic importance of subclinical markers of cardiovascular injury on long-term CVD risk. A number of prevention trials across the survivorship spectrum are under way, which include primary prevention (before or during cancer treatment), secondary prevention (after completion of treatment), and integrated approaches to manage modifiable cardiovascular risk factors. Ongoing multidisciplinary collaborations between the oncology, cardiology, primary care, and other subspecialty communities are essential to reduce therapeutic exposures and improve surveillance, prevention, and treatment of CVD in this high-risk population. |
|---|---|
| AbstractList | Cardiovascular disease (CVD), which includes cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction, is a major concern for long-term survivors of childhood cancer. There is clear evidence of increased risk of CVD largely attributable to treatment exposures at a young age, most notably anthracycline chemotherapy and chest-directed radiation therapy, and compounded by traditional cardiovascular risk factors accrued during decades after treatment exposure. Preclinical studies are limited; thus, it is a high priority to understand the pathophysiology of CVD as a result of anticancer treatments, taking into consideration the growing and developing heart. Recently developed personalized risk prediction models can provide decision support before initiation of anticancer therapy or facilitate implementation of screening strategies in at-risk survivors of cancer. Although consensus-based screening guidelines exist for the application of blood and imaging biomarkers of CVD, the most appropriate timing and frequency of these measures in survivors of childhood cancer are not yet fully elucidated. Longitudinal studies are needed to characterize the prognostic importance of subclinical markers of cardiovascular injury on long-term CVD risk. A number of prevention trials across the survivorship spectrum are under way, which include primary prevention (before or during cancer treatment), secondary prevention (after completion of treatment), and integrated approaches to manage modifiable cardiovascular risk factors. Ongoing multidisciplinary collaborations between the oncology, cardiology, primary care, and other subspecialty communities are essential to reduce therapeutic exposures and improve surveillance, prevention, and treatment of CVD in this high-risk population.Cardiovascular disease (CVD), which includes cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction, is a major concern for long-term survivors of childhood cancer. There is clear evidence of increased risk of CVD largely attributable to treatment exposures at a young age, most notably anthracycline chemotherapy and chest-directed radiation therapy, and compounded by traditional cardiovascular risk factors accrued during decades after treatment exposure. Preclinical studies are limited; thus, it is a high priority to understand the pathophysiology of CVD as a result of anticancer treatments, taking into consideration the growing and developing heart. Recently developed personalized risk prediction models can provide decision support before initiation of anticancer therapy or facilitate implementation of screening strategies in at-risk survivors of cancer. Although consensus-based screening guidelines exist for the application of blood and imaging biomarkers of CVD, the most appropriate timing and frequency of these measures in survivors of childhood cancer are not yet fully elucidated. Longitudinal studies are needed to characterize the prognostic importance of subclinical markers of cardiovascular injury on long-term CVD risk. A number of prevention trials across the survivorship spectrum are under way, which include primary prevention (before or during cancer treatment), secondary prevention (after completion of treatment), and integrated approaches to manage modifiable cardiovascular risk factors. Ongoing multidisciplinary collaborations between the oncology, cardiology, primary care, and other subspecialty communities are essential to reduce therapeutic exposures and improve surveillance, prevention, and treatment of CVD in this high-risk population. Cardiovascular disease (CVD), which includes cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction, is a major concern for long-term survivors of childhood cancer. There is clear evidence of increased risk of CVD largely attributable to treatment exposures at a young age, most notably anthracycline chemotherapy and chest-directed radiation therapy, and compounded by traditional cardiovascular risk factors accrued during decades after treatment exposure. Preclinical studies are limited; thus, it is a high priority to understand the pathophysiology of CVD as a result of anticancer treatments, taking into consideration the growing and developing heart. Recently developed personalized risk prediction models can provide decision support before initiation of anticancer therapy or facilitate implementation of screening strategies in at-risk survivors of cancer. Although consensus-based screening guidelines exist for the application of blood and imaging biomarkers of CVD, the most appropriate timing and frequency of these measures in survivors of childhood cancer are not yet fully elucidated. Longitudinal studies are needed to characterize the prognostic importance of subclinical markers of cardiovascular injury on long-term CVD risk. A number of prevention trials across the survivorship spectrum are under way, which include primary prevention (before or during cancer treatment), secondary prevention (after completion of treatment), and integrated approaches to manage modifiable cardiovascular risk factors. Ongoing multidisciplinary collaborations between the oncology, cardiology, primary care, and other subspecialty communities are essential to reduce therapeutic exposures and improve surveillance, prevention, and treatment of CVD in this high-risk population. |
| Author | Moslehi, Javid Kremer, Leontien C M van der Pal, Helena J Ky, Bonnie Ryan, Thomas D Chow, Eric J van Dalen, Elvira C Mulrooney, Daniel A Aune, Gregory Nathan, Paul C Ehrhardt, Matthew J Armenian, Saro H Armstrong, Gregory T |
| Author_xml | – sequence: 1 givenname: Saro H surname: Armenian fullname: Armenian, Saro H organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 2 givenname: Gregory T surname: Armstrong fullname: Armstrong, Gregory T organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 3 givenname: Gregory surname: Aune fullname: Aune, Gregory organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 4 givenname: Eric J surname: Chow fullname: Chow, Eric J organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 5 givenname: Matthew J surname: Ehrhardt fullname: Ehrhardt, Matthew J organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 6 givenname: Bonnie surname: Ky fullname: Ky, Bonnie organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 7 givenname: Javid surname: Moslehi fullname: Moslehi, Javid organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 8 givenname: Daniel A surname: Mulrooney fullname: Mulrooney, Daniel A organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 9 givenname: Paul C surname: Nathan fullname: Nathan, Paul C organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 10 givenname: Thomas D surname: Ryan fullname: Ryan, Thomas D organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 11 givenname: Helena J surname: van der Pal fullname: van der Pal, Helena J organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 12 givenname: Elvira C surname: van Dalen fullname: van Dalen, Elvira C organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 13 givenname: Leontien C M surname: Kremer fullname: Kremer, Leontien C M organization: Saro H. Armenian, City of Hope, Duarte, CA; Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis; Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN; Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX; Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA; Bonnie Ky, University of Pennsylvania, Philadelphia, PA; Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada; Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht; and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29874141$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM9LwzAcxYNM3A-9e5IcPdiZfNs0jTepUyeDDdRzSdt0jbRJTdrC_nsHTvD0Prz3eIc3RxNjjULompIlBULu39LtEgjlSx4vQwHkDM0oAx5wztjkH0_R3PsvQmiUhOwCTUEkPKIRnaE-la7UdpS-GBrp8JP2SnqFtcHvgxv1aJ3HtsJprZuytrbEqTSFcg94bbze170_Qm_xqtOlarVt7P5wh3eyr21XH_yfIU2Jd06NyvTamkt0XsnGq6uTLtDn8-ojfQ0225d1-rgJigigD3hc5DEAETyXMsyrKspjJkhSlbIMJSOQxyIXlBUCEhoKXsmKF_yYR4wDCRks0O3vbufs96B8n7XaF6pppFF28BkQRmPGBMCxenOqDnmryqxzupXukP09BT9AZm3A |
| CitedBy_id | crossref_primary_10_1093_eurheartj_ehaf617 crossref_primary_10_1186_s12875_024_02322_7 crossref_primary_10_1186_s40959_019_0047_4 crossref_primary_10_3390_children8100872 crossref_primary_10_1016_S2352_3026_21_00136_8 crossref_primary_10_3389_fcvm_2023_1232681 crossref_primary_10_1111_anec_70087 crossref_primary_10_3390_pharmaceutics15122712 crossref_primary_10_1002_cam4_6580 crossref_primary_10_1016_j_hlc_2023_04_301 crossref_primary_10_1007_s11886_019_1121_0 crossref_primary_10_1016_j_oraloncology_2024_107103 crossref_primary_10_1007_s11912_019_0751_0 crossref_primary_10_3389_fcvm_2022_974123 crossref_primary_10_2217_fca_2018_0030 crossref_primary_10_1542_peds_2023_061778 crossref_primary_10_3390_cancers15215158 crossref_primary_10_1002_cncr_35591 crossref_primary_10_1016_j_thromres_2022_01_003 crossref_primary_10_1002_ijc_33218 crossref_primary_10_1016_j_echo_2023_09_009 crossref_primary_10_1016_j_jaccao_2020_05_008 crossref_primary_10_1111_eci_14197 crossref_primary_10_1155_2021_8828410 crossref_primary_10_1007_s12170_020_00650_8 crossref_primary_10_1097_MOP_0000000000000675 crossref_primary_10_1542_pir_2022_005906 crossref_primary_10_3389_fmed_2023_1206071 crossref_primary_10_1002_pbc_31882 crossref_primary_10_1016_j_anpede_2024_503719 crossref_primary_10_1016_j_jaccao_2022_05_010 crossref_primary_10_1002_cncr_33974 crossref_primary_10_1111_micc_12625 crossref_primary_10_1002_prca_70021 crossref_primary_10_7759_cureus_85670 crossref_primary_10_1002_pbc_29720 crossref_primary_10_1016_j_anpedi_2024_503719 crossref_primary_10_1097_JMQ_0000000000000210 crossref_primary_10_1155_2022_4740931 crossref_primary_10_3390_life12010045 crossref_primary_10_1016_j_jacc_2019_12_019 crossref_primary_10_3389_fcvm_2022_1024846 crossref_primary_10_1136_bmjopen_2022_065776 crossref_primary_10_1016_j_banm_2022_03_009 crossref_primary_10_1089_jayao_2023_0130 crossref_primary_10_1016_j_jaccao_2022_02_002 crossref_primary_10_1016_j_prro_2024_10_004 crossref_primary_10_1093_ehjci_jeac106 crossref_primary_10_1002_hed_27054 crossref_primary_10_3389_fcvm_2023_1212174 crossref_primary_10_1007_s13187_020_01843_w crossref_primary_10_1093_eurheartj_ehac244 crossref_primary_10_1080_08880018_2021_1894279 crossref_primary_10_1007_s11912_019_0796_0 crossref_primary_10_1002_cncr_32356 crossref_primary_10_1016_S0140_6736_19_31674_5 crossref_primary_10_1053_j_jvca_2020_02_052 crossref_primary_10_3390_cancers16071352 crossref_primary_10_1016_j_ijcard_2021_04_038 crossref_primary_10_1161_JAHA_119_013755 crossref_primary_10_26442_20751753_2025_8_203064 crossref_primary_10_1097_RTI_0000000000000430 crossref_primary_10_1016_j_cpcardiol_2022_101544 crossref_primary_10_2340_1651_226X_2025_43654 crossref_primary_10_1002_pbc_29783 crossref_primary_10_1200_JCO_18_01421 crossref_primary_10_1016_j_thromres_2023_04_025 crossref_primary_10_3390_curroncol32040214 crossref_primary_10_1016_j_jgo_2019_01_018 crossref_primary_10_1186_s13148_023_01447_3 crossref_primary_10_1016_j_cjca_2021_02_001 crossref_primary_10_1093_jnci_djae046 crossref_primary_10_1016_j_ijrobp_2018_08_034 crossref_primary_10_1016_j_jaccao_2024_06_006 crossref_primary_10_1016_j_jaccao_2025_06_001 crossref_primary_10_1016_j_jaccao_2020_08_006 crossref_primary_10_1016_j_semcancer_2025_06_011 crossref_primary_10_1007_s10787_021_00894_9 crossref_primary_10_3390_children12091171 crossref_primary_10_17826_cumj_1618661 crossref_primary_10_3389_fonc_2021_710163 crossref_primary_10_3390_jcm12082782 crossref_primary_10_3390_nu12010057 crossref_primary_10_1186_s40959_023_00188_9 crossref_primary_10_1007_s11912_022_01220_4 crossref_primary_10_1007_s00112_023_01831_6 crossref_primary_10_7759_cureus_63138 crossref_primary_10_1016_j_ejon_2024_102541 crossref_primary_10_3390_nu14163279 crossref_primary_10_3390_ph15081007 crossref_primary_10_1080_1120009X_2021_1873632 crossref_primary_10_1016_S1470_2045_23_00637_X crossref_primary_10_1158_0008_5472_CAN_21_0137 crossref_primary_10_3389_fcvm_2023_1186679 crossref_primary_10_1097_RMR_0000000000000276 crossref_primary_10_1186_s40959_025_00349_y crossref_primary_10_1017_S1047951124000076 crossref_primary_10_2459_JCM_0000000000001681 crossref_primary_10_3389_fped_2020_00123 crossref_primary_10_3390_jcm11030628 crossref_primary_10_1007_s11912_023_01368_7 crossref_primary_10_1007_s11886_022_01641_4 crossref_primary_10_3389_fcvm_2023_1124276 crossref_primary_10_1200_JCO_2018_79_0477 crossref_primary_10_21518_ms2025_275 crossref_primary_10_3390_nu16091315 crossref_primary_10_1038_s43856_022_00081_z crossref_primary_10_1111_cge_13968 crossref_primary_10_1016_j_rec_2023_05_001 crossref_primary_10_3389_fonc_2020_611514 crossref_primary_10_1001_jamanetworkopen_2023_47449 crossref_primary_10_1001_jamanetworkopen_2024_2727 crossref_primary_10_1093_jnci_djy229 crossref_primary_10_3389_fonc_2022_947604 crossref_primary_10_1089_jayao_2024_0054 crossref_primary_10_31362_patd_815376 crossref_primary_10_3390_cancers15123150 crossref_primary_10_1016_j_jacadv_2022_100155 crossref_primary_10_3389_fcvm_2021_715953 crossref_primary_10_3390_children10061073 crossref_primary_10_1186_s43044_024_00506_1 crossref_primary_10_1017_S1047951123004213 crossref_primary_10_1177_15598276251368342 crossref_primary_10_1007_s12265_020_10010_x crossref_primary_10_1186_s40959_019_0054_5 crossref_primary_10_1002_phar_2638 crossref_primary_10_7554_eLife_62852 crossref_primary_10_1371_journal_pone_0238856 crossref_primary_10_1002_cncr_32945 crossref_primary_10_1161_JAHA_120_018403 crossref_primary_10_1038_s41598_023_39357_2 crossref_primary_10_1002_pbc_28012 crossref_primary_10_1186_s40959_023_00193_y crossref_primary_10_3389_fcvm_2023_1223660 crossref_primary_10_1158_1078_0432_CCR_23_1055 crossref_primary_10_1210_clinem_dgae196 crossref_primary_10_1002_cam4_71116 crossref_primary_10_1186_s12885_023_11353_9 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2017.76.3920 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 29874141 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL118018 |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP ABBLC ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL BYPQX C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 K-O KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YFH YQY 7X8 |
| ID | FETCH-LOGICAL-c422t-76cb622097baa3bff4b65908fdad3a502b69b915c9281397faf7c708f45720352 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 156 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000439294100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Tue Aug 05 09:55:25 EDT 2025 Mon Jul 21 05:56:58 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 21 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c422t-76cb622097baa3bff4b65908fdad3a502b69b915c9281397faf7c708f45720352 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/6804893 |
| PMID | 29874141 |
| PQID | 2051655922 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2051655922 pubmed_primary_29874141 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-07-20 |
| PublicationDateYYYYMMDD | 2018-07-20 |
| PublicationDate_xml | – month: 07 year: 2018 text: 2018-07-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2018 |
| SSID | ssj0014835 |
| Score | 2.617658 |
| SecondaryResourceType | review_article |
| Snippet | Cardiovascular disease (CVD), which includes cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2135 |
| SubjectTerms | Anthracyclines - administration & dosage Anthracyclines - adverse effects Cancer Survivors - statistics & numerical data Cardiovascular Diseases - epidemiology Cardiovascular Diseases - physiopathology Cardiovascular Diseases - prevention & control Child Humans Neoplasms - drug therapy Neoplasms - epidemiology |
| Title | Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29874141 https://www.proquest.com/docview/2051655922 |
| Volume | 36 |
| WOSCitedRecordID | wos000439294100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7UinjxUV_1xQrSU6PJJpvNehGJLSq2BnzQW9ndJNBLUpu00H_vbJIaPAiCBEJICFl2J5Nv5pvMh9Al5VzIKILoxOWubqodGoIJZYSeCGUc20IVOmQfz2ww8IZDHlQJt6wqq1z6xMJRh6nSOXII0qnlAvwl5HbyaWjVKM2uVhIaq6hhA5TRVs2GNYvgeIXAplZuBRRJaUVTgmFcP_kvuq6LXTEXwn5i_g4wiw9Nb_u_Q9xBWxXExHelTeyilShpoo1-RaI3UTso21UvOvit_vsq6-A2DupG1os9lPs_ilXxfUnm4HGCX2fgYubpNMNpjL_bI2Nf29D0Bj8mmQ76MzjIU9ytVWjhmQFgzrRIqFQnRBLiZSepNNlH773um_9gVCoNhnIIyQ3mKukSYnImhbBhfR3paiH1OBShLahJpMslt6jixNNwMxYxUwyuO1RTwJQcoLUkTaIjhAFcOkoTeYzqwE1xKWCDIF2GkaVMp4UulhM_grdAUxsiidJZNqqnvoUOy9UbTcp2HSPCPYBNjnX8h7tP0CZYhaeTt8Q8RY0YfEB0htbVPB9n0_PCvGA_CPpfV47bjg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardiovascular+Disease+in+Survivors+of+Childhood+Cancer%3A+Insights+Into+Epidemiology%2C+Pathophysiology%2C+and+Prevention&rft.jtitle=Journal+of+clinical+oncology&rft.au=Armenian%2C+Saro+H&rft.au=Armstrong%2C+Gregory+T&rft.au=Aune%2C+Gregory&rft.au=Chow%2C+Eric+J&rft.date=2018-07-20&rft.issn=1527-7755&rft.eissn=1527-7755&rft.volume=36&rft.issue=21&rft.spage=2135&rft_id=info:doi/10.1200%2FJCO.2017.76.3920&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |